BR0115938A - Derivados de guanidina e amidina com inibidores do fator xa - Google Patents

Derivados de guanidina e amidina com inibidores do fator xa

Info

Publication number
BR0115938A
BR0115938A BR0115938-0A BR0115938A BR0115938A BR 0115938 A BR0115938 A BR 0115938A BR 0115938 A BR0115938 A BR 0115938A BR 0115938 A BR0115938 A BR 0115938A
Authority
BR
Brazil
Prior art keywords
factor
compounds
inhibitors
formula
guanidine
Prior art date
Application number
BR0115938-0A
Other languages
English (en)
Inventor
Anuschirwan Peyman
Original Assignee
Aventis Pharma Deustschland Gm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deustschland Gm filed Critical Aventis Pharma Deustschland Gm
Publication of BR0115938A publication Critical patent/BR0115938A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"DERIVADOS DE GUANIDINA E AMIDINA COMO INIBIDORES DO FATOR XA". A presente invenção refere-se a compostos da fórmula I, onde R~ 0~, Q, X, Q, D, R~ 10~ e V têm os significados indicados nas reivindicações. Os compostos da fórmula I são compostos farmacologicamente ativos valiosos. Eles apresentam um forte efeito antitrombótico e são adequados, por exemplo, para a terapia e a profilaxia de distúrbios cardiovasculares como doenças tromboembólicas ou restenoses. Eles são inibidores reversíveis das enzimas de coagulação do sangue fator Xa (FXa) e/ou fator Vlla (FVlla), e em geral podem ser aplicados em condições em que esteja presente uma atividade indesejada do fator Xa e/ou do fator Vlla ou para cuja cura ou prevenção se deseja uma inibição do fator Xa e/ou do fator Vlla. A invenção referese ainda a processos para a preparação de compostos da fórmula (I), seus uso, em particular como ingredientes ativos em farmacêuticos, e preparados farmacêuticos compreendendo os mesmos.
BR0115938-0A 2000-12-06 2001-11-28 Derivados de guanidina e amidina com inibidores do fator xa BR0115938A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126750 2000-12-06
PCT/EP2001/013874 WO2002046159A1 (en) 2000-12-06 2001-11-28 Guanidine and amidine derivatives as factor xa inhibitors

Publications (1)

Publication Number Publication Date
BR0115938A true BR0115938A (pt) 2003-12-23

Family

ID=8170585

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115938-0A BR0115938A (pt) 2000-12-06 2001-11-28 Derivados de guanidina e amidina com inibidores do fator xa

Country Status (26)

Country Link
US (2) US20020173656A1 (pt)
EP (1) EP1345900B1 (pt)
JP (1) JP4274522B2 (pt)
KR (1) KR20040015036A (pt)
CN (1) CN1479722A (pt)
AR (1) AR033684A1 (pt)
AU (2) AU3320602A (pt)
BR (1) BR0115938A (pt)
CA (1) CA2430518C (pt)
CZ (1) CZ20031554A3 (pt)
DE (1) DE60126143T2 (pt)
DK (1) DK1345900T3 (pt)
EE (1) EE200300192A (pt)
ES (1) ES2278798T3 (pt)
HR (1) HRP20030447A2 (pt)
HU (1) HUP0302604A3 (pt)
IL (2) IL156214A0 (pt)
MX (1) MXPA03004848A (pt)
NO (1) NO20032489L (pt)
NZ (1) NZ526269A (pt)
PL (1) PL362320A1 (pt)
PT (1) PT1345900E (pt)
RU (1) RU2003120070A (pt)
SK (1) SK6862003A3 (pt)
WO (1) WO2002046159A1 (pt)
ZA (1) ZA200303847B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1703395A (zh) * 2002-08-09 2005-11-30 特兰斯泰克制药公司 芳基和杂芳基化合物以及调节凝血的方法
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
WO2005014533A2 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US8603481B2 (en) * 2003-10-10 2013-12-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for solid tumors
ATE483708T1 (de) 2004-03-08 2010-10-15 Prosidion Ltd Pyrrolopyridin-2-carbonsäurehydrazide als inhibitoren von glykogenphosphorylase
ATE424821T1 (de) 2004-12-02 2009-03-15 Prosidion Ltd Pyrrolopyridin-2-karbonsäureamide
DE102006048300A1 (de) * 2006-01-26 2007-08-02 Hellstern, Peter, Prof. Dr.med. Inhibitoren des Blutgerinnungsfaktors Xa zur Verwendung als Antikoagulans
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
US8507640B2 (en) 2010-08-19 2013-08-13 International Business Machines Corporation Methods of ring opening polymerization and catalysts therefor
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
MA49566A (fr) 2017-07-11 2020-05-20 Vertex Pharma Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
IL272838B2 (en) 2017-10-06 2023-09-01 Forma Therapeutics Inc Peptidase-specific ubiquitin inhibition 30
SG11202011299PA (en) 2018-05-17 2020-12-30 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
PE20211053A1 (es) 2018-10-05 2021-06-07 Forma Therapeutics Inc Inhibicion de la proteasa 30 especifica de la ubiquitina (usp30)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201303B (pt) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
ES2103181B1 (es) * 1994-08-01 1998-04-01 Menarini Lab Amidas naftalenicas con accion antagonista de los leucotrienos.
SK286094B6 (sk) * 1994-04-26 2008-03-05 Aventis Pharmaceuticals Inc. Zlúčenina špecificky inhibujúca aktivitu faktora Xa, farmaceutická kompozícia s jej obsahom a jej použitie
US5792769A (en) * 1995-09-29 1998-08-11 3-Dimensional Pharmaceuticals, Inc. Guanidino protease inhibitors
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
TW542822B (en) * 1997-01-17 2003-07-21 Ajinomoto Kk Benzamidine derivatives
US6417200B1 (en) * 1997-06-26 2002-07-09 Eli Lilly And Company Antithrombotic agents
BR9909086A (pt) * 1998-03-23 2001-09-04 Aventis Pharm Prod Inc Derivados de piperidinila e n-amidinopiperidinila
US20020016339A1 (en) * 1998-03-23 2002-02-07 Klein Scott I. Piperididinyl and N-amidinopiperidinyl derivatives
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
KR20020047175A (ko) * 1999-09-17 2002-06-21 밀레니엄 파머슈티컬스 인코퍼레이티드 Xa 인자의 억제제

Also Published As

Publication number Publication date
EP1345900A1 (en) 2003-09-24
IL156214A0 (en) 2003-12-23
KR20040015036A (ko) 2004-02-18
HUP0302604A3 (en) 2005-09-28
NO20032489D0 (no) 2003-06-02
AU2002233206B2 (en) 2006-06-22
HRP20030447A2 (en) 2005-04-30
CA2430518A1 (en) 2002-06-13
EP1345900B1 (en) 2007-01-17
ZA200303847B (en) 2004-04-15
RU2003120070A (ru) 2004-12-27
CA2430518C (en) 2010-06-15
DK1345900T3 (da) 2007-05-21
WO2002046159A1 (en) 2002-06-13
SK6862003A3 (en) 2004-02-03
AU3320602A (en) 2002-06-18
PT1345900E (pt) 2007-03-30
EE200300192A (et) 2003-08-15
CZ20031554A3 (cs) 2003-08-13
HUP0302604A2 (hu) 2003-11-28
JP2004515492A (ja) 2004-05-27
NZ526269A (en) 2004-11-26
NO20032489L (no) 2003-07-25
US20020173656A1 (en) 2002-11-21
DE60126143D1 (de) 2007-03-08
MXPA03004848A (es) 2003-08-19
PL362320A1 (en) 2004-10-18
IL156214A (en) 2010-05-31
AR033684A1 (es) 2004-01-07
DE60126143T2 (de) 2007-11-15
CN1479722A (zh) 2004-03-03
JP4274522B2 (ja) 2009-06-10
US7435747B2 (en) 2008-10-14
US20050143419A1 (en) 2005-06-30
ES2278798T3 (es) 2007-08-16

Similar Documents

Publication Publication Date Title
BR0116473A (pt) Derivados de oxibenzamidas como inibidores de fator xa
BR0214396A (pt) Indol-2-carboxamidas como inibidores de fator xa
BR0317659A (pt) Derivados de pirazol como inibidores de fator xa
BR0111264A (pt) Derivados (tio) uréia inibidores do fator viia, sua preparação e sua utilização
BR0115938A (pt) Derivados de guanidina e amidina com inibidores do fator xa
BRPI0508048A (pt) derivados de pirrol como inibidores do fator xa
BRPI0508320A (pt) derivados de beta-aminoácido como inibidores do fator xa
BR0313240A (pt) Cicloalquenilaminas condensadas por heteroarila, acilas e seu uso como farmacêuticos
PA8603601A1 (es) Nuevos derivados de indol como inhibidores del factor xa.
TW200510400A (en) Indazole-derivatives as factor Xa inhibitors
MXPA03011022A (es) Derivados de urea con actividad antiproteolitica.
BR0015186A (pt) N-guanidinoalquilamidas, sua preparação, seu uso, e preparações farmacêuticas compreendendo-as
BR0011461A (pt) Inibidores do fator viia
TNSN05297A1 (en) BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
BR0317003A (pt) Derivados de imidazol como inibidores do fator xa
TNSN05296A1 (en) AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
BR0207981A (pt) Derivados de imidazolidina, sua preparação, e seu uso como agente antiinflamatório
JO2467B1 (en) New indole derivatives as an inhibitor of Xa

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH (DE)

Free format text: ALTERADO DE: AVENTIS PHARMA DEUTSCHLAND GMBH

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.